Perioperative Smoking Cessation BUndle in a Tertiary Care Hospital - Can Turning Virtual Improve Outcomes? (BuTT-Out)

Perioperative Smoking Cessation BUndle in a Tertiary Care Hospital - Can Turning Virtual Improve Outcomes? A Pilot Randomized Controlled Trial.

Smoking continues to be a burden to the healthcare system in Canada. It is well-known that smokers suffer more complications and higher risk of mortality after surgery than non-smokers. A quality improvement project at Royal Columbian Hospital recently showed that it is possible to implement a smoking cessation bundle for all current smokers during their preadmission clinic visit. However, due to the COVID-19 pandemic, much of the bundle was abandoned as it relied heavily on in-person interactions. The investigators wish to study the effect of a structured smoking cessation bundle, delivered remotely, on smoking cessation and postoperative complications. The aim is to determine the feasibility of giving the remotely delivered bundle to elective surgical patients before or around the time of a preadmission clinic visit, and whether it can reduce smoking rates and postoperative complications versus the standard uncoordinated advice.

Study Overview

• Status: Active, not recruiting
• Conditions: Smoking Cessation; Surgical Complications
• Intervention / Treatment: Other: Remote smoking cessation bundle

Detailed Description

Introduction and Background Smoking continues to be a burden to the healthcare system in Canada. As of 2019, 3.7 million Canadians (12% of the population over age 15) reported being a current smoker. British Columbia's smoking rate is lower, but 10.2% of adults still regularly smoke cigarettes1. It is well-known that smokers suffer more complications and higher risk of mortality after surgery than non-smokers. Pulmonary complications, cardiovascular complications, and surgical site infections are mediators of smoking-associated mortality at 6-months and 1-year after elective surgery.

Although there have been a handful of studies that have demonstrated dramatic reductions in postoperative complications with well-timed smoking cessation interventions in the preoperative period, these results have not translated into widespread clinical practice in delaying surgery for the purpose of achieving smoking cessation. In addition, most of these studies took place in Europe, where smokers may behave differently than in the Canadian setting.

A systematic review recommended at least 4 weeks of smoking cessation in order to reduce postoperative complications6. Several European studies have shown dramatic reductions in complications (up to 30% absolute risk reductions) when smoking cessation interventions have been implemented 4-8 weeks preoperatively. One Canadian editorial even suggested new policies be put into place to delay elective surgeries in smokers until a trial of cessation for 6 weeks had taken place.

Implementation of smoking cessation programs preoperatively have the potential to reduce morbidity and mortality. A Cochrane systematic review has shown that preoperative smoking cessation therapy improves both short and long-term smoking cessation. In fact, a surgical encounter with the healthcare system has been described as a "teachable moment" that provides motivation for patients to permanently stop smoking. Despite this information, most anesthesiologists do not routinely offer smoking cessation advice to their patients and advice, counselling, and pharmacotherapy for smoking cessation is not routine in pre-admission clinics across Canada and the United States.

Several small trials have shown that smoking cessation interventions can increase smoking cessation and reduce postoperative complications, particularly wound-healing complications, which can have an absolute risk reduction of up to 25%. Prior work by one of the co-investigators showed that a simple intervention in the pre-admission clinic was able to increase the abstinence rate from 3.6% to 14.3% on the day of surgery. Smoking cessation initiated in the perioperative period can also promote long-term smoking cessation.

Despite these successes, since the COVID-19 pandemic, standard care at Royal Columbian Hospital (RCH) has not routinely included specific preoperative smoking cessation pharmacotherapy or counselling. However, hospital leaders and the RCH Department of Anesthesia have identified preoperative preparation, including smoking cessation, as a key area of interest for development. Therefore, this is the ideal time to study the feasibility of the perioperative smoking cessation bundle given to patients without the requirement for an in-person visit. Advantages of this remote model are expected to continue after the pandemic restrictions end, since smoking cessation bundles will be able to be started earlier (and thus have more potential to prevent surgical complications), compared to waiting for a preadmission clinic visit, which can often occur only a few days preoperatively. The perioperative smoking cessation bundle will include: an emailed link to a quitnow.ca preoperative smoking cessation video and referral to quit coach, free nicotine replacement therapy (NRT) delivered by an online pharmacy, an emailed or post-mailed RCH smoking cessation brochure, and brief telephone advice. This bundle will be offered to those regular smokers of cigarettes randomized to the intervention group following their surgical consultation, at the time of preadmission clinic appointment booking, or following their preadmission telephone consultation. The control group will receive the standard of care which sometimes includes brief advice and informing patients about availability of further aids.

Once the simple smoking cessation intervention has been implemented for the intervention group, the investigators wish to compare rates of resource access, smoking cessation, and postoperative complications between the group receiving the smoking cessation bundle and those receiving standard care. Due to the COVID-19 pandemic, in-person preadmission clinic visits are no longer scheduled. Instead, high-risk surgical patients are phoned prior to surgery to mitigate surgical risk factors and better prepare them for surgery. Self-identification as a regular smoker is one risk factor that would warrant recruitment into the study.

The investigators estimated that a definitive randomized controlled trial would require a sample size of 214 participants. However, relatively low rates of smoking in British Columbia and the cancellation of in-person preadmission clinic visits present a unique challenge to patient recruitment. It is therefore imperative to establish the recruitment rate for progression to a full randomized controlled trial.

Additionally, a preliminary analysis of rates of smoking and reduction of postoperative complications in elective surgical patients when the smoking cessation bundle is given to patients immediately following their preadmission clinic telephone consultation will be conducted. The investigators plan to carry out a pilot randomized controlled trial where patients who identify as smokers will be randomized to receive the remotely delivered smoking cessation bundle versus standard care.

Purpose and Justification Most randomized studies showing improved smoking cessation rates after preoperative interventions have strict inclusion and exclusion criteria, and required ongoing consent for research experimentation, which limits their external generalizability. The BuTT Out Pilot Study is of utmost importance since it has the potential to demonstrate reductions in surgical site infections and lengths-of-stay using a low-cost intervention (a bundle of emailed video, brochure, helpline referral and government funded smoking-cessation therapy). A 2020 survey of the BC Smoking Cessation Program reported that 66% of respondents found the program helpful, with a quit rate of 37%. Providing the program as a part of a structured bundle will improve the accessibility of smoking cessation aids. If this hypothesis is confirmed as suspected since it is based on prior research in other countries, widespread implementation could translate into tremendous advantages for the patient, in terms of reduced complications, and providers, in terms of cost savings. Conducting a pilot study will help mitigate the challenge of recruiting an adequate sample size by establishing a recruitment rate and consequently improve the feasibility of a definitive randomized controlled trial. Since this study will examine remotely-delivered interventions, its potential for widespread use will be much greater than other previously studied in-person study designs.

Research Question For patients who smoke undergoing elective surgery, what is the effect of an evidence-based remotely-delivered smoking cessation bundle administered preoperatively on patients' outcomes (smoking rates, complication rates and hospital length of stay) compared with standard practice which sometimes includes brief advice and informing patients about availability of further aids?

Research Objectives To establish the recruitment rate, optimal recruitment pathway, and rate of accessing of available resources as criteria for progression to a definitive randomized controlled trial.

To determine whether smoking rates, surgical complications, and postoperative complications can be documented in elective surgical patients when the remotely-delivered smoking cessation bundle is administered preoperatively vs. standard care.

Research Hypothesis The hypothesis for this pilot RCT is that at least 8 patients will be screened per week, at least 25% will give informed consent, and >80% will adhere to the study protocol.

The overarching research hypothesis is that in patients who smoke, receiving the remotely-delivered perioperative smoking cessation bundle prior to elective surgery for the purpose of quitting smoking will result in reduced smoking rates on the day of surgery, lower 30-day complications, and shorter lengths of stay. Definitive estimation of effect size is not expected from this pilot study, but confidence intervals will give rise to sample size estimation for a future full-size trial.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Susan M Lee, MD, FRCPC; Phone Number: 604-520-4253; Email: suze.lee@utoronto.ca
• Study Contact Backup: Name: Michelle Mozel, MSc; Phone Number: 604-520-4253; Email: michelle.mozel@fraserhealth.ca

Study Locations

• Canada
  • British Columbia
    • New Westminster, British Columbia, Canada, V3L 3W7
      • Royal Columbian Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Adults aged 18 years and over.
2. Current smoker (self-identified from pre-surgical package).
3. Surgery date over 1 week away or not yet booked.

Exclusion criteria

1. Emergency surgery.
2. Smokers who only consume non-cigarette forms of tobacco (pipe, smokeless tobacco).
3. Smokers who only consume marijuana or vaping.
4. Patients who are pregnant or breastfeeding.
5. Inability to provide informed consent.
6. Currently enrolled in any other research study involving smoking cessation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
No Intervention: Control group; The control group will have their preadmission clinic telephone call as normal and may be given advice to quit smoking and information about available smoking cessation resources over the phone.
Experimental: Intervention group; The intervention group will be emailed (or postal mailed) the smoking cessation bundle with educational video, brochure, referral to the Smokers' Helpline and direct referral to an online pharmacy for nicotine replacement.	Other: Remote smoking cessation bundle; The bundle is a remote version of what has previously been described in prior literature, which includes: A brief (<5 minutes) advice; Preoperative smoking cessation video prepared by QuitNow; Patients will be provided brochures on smoking cessation; A referral will be faxed (or internet-registered) to the Quitnow.ca Smokers' Helpline; All patients will be requested to participate in the provincial Smoking Cessation program that provides a free 12-week supply of NRT once per year.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Uptake of smoking cessation resources	The primary outcome is the participant's self-reported rate of uptake of smoking cessation information and accessing available resources. Uptake will be assessed by a brief questionnaire given at each of the follow-up time points asking which resources were accessed and if NRT was used.	Day of surgery
Uptake of smoking cessation resources	The primary outcome is the participant's self-reported rate of uptake of smoking cessation information and accessing available resources. Uptake will be assessed by a brief questionnaire given at each of the follow-up time points asking which resources were accessed and if NRT was used.	30 days postoperatively
Uptake of smoking cessation resources	The primary outcome is the participant's self-reported rate of uptake of smoking cessation information and accessing available resources. Uptake will be assessed by a brief questionnaire given at each of the follow-up time points asking which resources were accessed and if NRT was used.	8 weeks post-randomization
Uptake of smoking cessation resources	The primary outcome is the participant's self-reported rate of uptake of smoking cessation information and accessing available resources. Uptake will be assessed by a brief questionnaire given at each of the follow-up time points asking which resources were accessed and if NRT was used.	6 months postoperatively

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recruitment rate	Number of eligible patients consented out of all eligible patients	Enrollment
Recruitment timing	Duration between enrollment and day of surgery	Enrollment
Participant satisfaction with smoking cessation bundle assessed by study questionnaire	Open-ended questions asking how satisfied participants were with the smoking cessation bundle, which parts of the bundle were most and least helpful	8 weeks post-randomization
Change in smoking status from baseline	Self-report of smoking status at each time point compared to baseline (defined as number of cigarettes smoked in the last 24 hours)	Day of surgery, 30 days postoperatively, 8 weeks post-randomization and 6 months postoperatively
Hospital Length of Stay	Length of time the participant is admitted to the hospital for their surgical procedure.	First 30 days
Postop complications (day 3 POMS)	Day 3 Postoperative Morbidity Survey (POMS).	Postop Day 3
Cost of nicotine replacement therapy	Total cost of NRT prescriptions supplied	6 months
Number of nicotine replacement therapy refills	For those using NRT, how many times did they refill their NRT prescription	6 months
Number of nicotine replacement therapy pharmacy deliveries	For those using NRT, how many pharmacy deliveries of NRT did they get	6 months

Collaborators and Investigators

• Sponsor: Fraser Health
• Collaborators: Royal Columbian Hospital Foundation
• Investigators: Principal Investigator: Susan M Lee, MD, FRCPC, Fraser Health Authority; Study Chair: Michelle Mozel, MSc, Fraser Health Authority

Study record dates

Study Major Dates

• Study Start (Actual): February 24, 2022
• Primary Completion (Estimated): January 1, 2024
• Study Completion (Estimated): January 1, 2024

Study Registration Dates

• First Submitted: March 16, 2018
• First Submitted That Met QC Criteria: July 22, 2020
• First Posted (Actual): July 27, 2020

Study Record Updates

• Last Update Posted (Actual): September 13, 2023
• Last Update Submitted That Met QC Criteria: September 11, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Surgery; Smoking; Complications; Anesthesia
• Other Study ID Numbers: FHREB 2017-099

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No